Extraperitoneal Open Radical Cystectomy: A New Standard in Frail Patients with Muscle-Invasive Bladder Cancer?

被引:0
作者
Porav-Hodade, Daniel [1 ,2 ]
Big, Silvestru-Alexandru [3 ]
Barbos, Vlad-Ilie [3 ]
Gherle, Bogdan [4 ]
Jerzicska, Erno [5 ]
Ona, Victor [6 ]
Feciche, Bogdan-Ovidiu [3 ,7 ]
机构
[1] George Emil Palade Univ Med & Pharm Sci & Technol, Dept Urol, Targu Mures 540139, Romania
[2] Clin Cty Hosp Mures, Dept Urol, Targu Mures 540136, Romania
[3] Bihor Emergency Clin Cty Hosp, Dept Urol, Oradea 410169, Romania
[4] Univ Oradea, Doctoral Sch Biol & Biomed Sci, Domain Biol, 1 Univ St, Oradea 410081, Romania
[5] Bihor Emergency Clin Cty Hosp, Dept Cardiovasc Surg, Oradea 410169, Romania
[6] Clin Municipal Hosp, Dept Radiol, Cluj Napoca 400139, Romania
[7] Univ Oradea, Fac Med & Pharm, Dept Urol, 1 Univ St, Oradea 410087, Romania
关键词
bladder cancer; extraperitoneal open radical cystectomy; reperitonization; frailty; COMPLICATIONS; MORTALITY;
D O I
10.3390/clinpract14060201
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objectives: Radical cystectomy (RC) represents one of the most complex and morbid surgical procedures in the field of Urology. Extraperitoneal open RC has emerged as an alternative to the traditional transperitoneal approach for the treatment of muscle-invasive bladder cancer. Frailty is one of the most important risk factors for perioperative morbidity and mortality, and this category of patients can benefit the most from the extraperitoneal approach. The purpose of this study was to evaluate the feasibility and the safety of extraperitoneal open RC in our experience; Methods: We retrospectively collected the data of 75 frail patients who underwent an extraperitoneal open RC, performed by a single experienced surgeon. We assessed their frailty status using the simplified frailty index (sFI). We recorded data regarding general characteristics, intraoperative, pathological, and postoperative complications, and mortality (within 90 days); Results: We analyzed 61 males and 14 females with an sFI equal to or higher than 3. The median age was 77 years. Fifty-one patients had an ASA score of 3 or more. Sixty procedures were with radical intention, while fifteen were palliative. Cutaneous ureterostomy was performed in 70 cases and extraperitonized ileal conduit in five cases. The median operative time was 150 min. The median blood loss was 400 mL. The median time to flatus was 2 days. The median postoperative stay was 7 days. Thirteen patients had Clavien-Dindo III or IV complications. Two patients died in first 90 days postoperatively; Conclusions: The extraperitoneal open RC in frail patients was demonstrated to be a feasible and safe alternative approach in definitive treatment or a palliative setting in our experience.
引用
收藏
页码:2559 / 2567
页数:9
相关论文
共 33 条
  • [1] Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J. Clin, 71, pp. 209-249, (2021)
  • [2] Martha O., Balan D., Porav-Hodade D., Dragus E., Vartolomei M.D., Chibelean C.B., Borda A., Pytel A., Vida O.A., The role of neutrophil to lymphocyte ratio in patients with pTa non-muscle invasive bladder cancer, Rev. Romana De Med. De Lab, 28, pp. 29-38, (2020)
  • [3] Antoni S., Ferlay J., Soerjomataram I., Znaor A., Jemal A., Bray F., Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends, Eur. Urol, 71, pp. 96-108, (2017)
  • [4] Teoh J.Y.-C., Huang J., Ko W.Y.-K., Lok V., Choi P., Ng C.-F., Sengupta S., Mostafid H., Kamat A.M., Black P.C., Et al., Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita, Eur. Urol, 78, pp. 893-906, (2020)
  • [5] Wong M.C.S., Fung F.D.H., Leung C., Cheung W.W.L., Goggins W.B., Ng C.F., The global epidemiology of bladder cancer: A joinpoint regression analysis of its incidence and mortality trends and projection, Sci. Rep, 8, (2018)
  • [6] Burger M., Catto J.W.F., Dalbagni G., Grossman H.B., Herr H., Karakiewicz P., Kassouf W., Kiemeney L.A., La Vecchia C., Shariat S., Et al., Epidemiology and risk factors of urothelial bladder cancer, Eur. Urol, 63, pp. 234-241, (2013)
  • [7] Witjes J.A., Bruins H.M., Carrion A., Cathomas R., Comperat E., Efstathiou J.A., Fietkau R., Gakis G., Lorch A., Martini A., Et al., European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines, Eur. Urol, 85, pp. 17-31, (2024)
  • [8] Babjuk M., Burger M., Comperat E.M., Gontero P., Mostafid A.H., Palou J., van Rhijn B.W.G., Roupret M., Shariat S.F., Sylvester R., Et al., European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ), Eur. Urol, 81, pp. 75-94, (2022)
  • [9] Holzbeierlein J., Bixler B.R., Buckley D.I., Chang S.S., Holmes R.S., James A.C., Kirkby E., McKiernan J.M., Schuckman A., Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017
  • [10] Amended 2020, 2024), J. Urol, 212, pp. 3-10, (2024)